Telix Pharmaceuticals Expands Through $3.3 Billion Radiopharmaceutical Deal

 Australian radiopharmaceutical company Telix Pharmaceuticals is set to expand its global presence through a major deal with German isotope specialist ITM Isotope Technologies Munich, in a transaction valued at up to $3.3 billion.

The ASX-listed company has agreed to acquire ITM in a deal involving an upfront payment of at least US$1.65 billion, or approximately $2.3 billion, in Telix shares. ITM is a privately owned company specialising in the production and supply of medical radioisotopes and has a distribution network reaching more than 65 countries.

Telix chief executive and managing director Dr Christian Behrenbruch described the agreement as a significant development for both companies. The transaction is expected to combine Telix's expertise in radiopharmaceutical medicines with ITM's capabilities in isotope production and supply.

Although the companies have referred to the arrangement as a merger, Telix shareholders are expected to hold approximately 76.3 per cent of the combined business, while ITM shareholders would retain around 23.7 per cent.

Strengthening Telix's Radiopharmaceutical Supply Chain

Telix develops radioactive medicines used in medical imaging and cancer treatment. Its established products include radiopharmaceutical agents used to help detect prostate cancer during PET scans by identifying cancerous tissue.

The company has also expanded its diagnostic portfolio. The US Food and Drug Administration recently approved Pixclara, an imaging agent designed to help identify gliomas, which are a common type of malignant brain tumour.

The proposed ITM transaction would give Telix greater control over an important part of its supply chain. ITM has significant inventories of radioisotopes including lutetium-177, actinium-225 and terbium-161, which are used in the development and production of cancer treatments.

Telix believes greater vertical integration could strengthen its ability to manage isotope supply as demand for radiopharmaceutical medicines continues to grow.

ITM's Role in the Global Isotope Market

ITM has established itself as an important supplier within the international radiopharmaceutical industry. Among its customers is Swiss pharmaceutical company Novartis, which has a major presence in radioligand therapies.

ITM supplies lutetium-177 used in Novartis' Pluvicto, a prostate cancer treatment that has become a significant product in the company's oncology portfolio.

The global market for medical radioisotopes is also expected to expand considerably over the coming decade. Growing investment in targeted cancer treatments and diagnostic imaging is increasing demand for specialised radioactive materials.

However, ITM has also experienced challenges. The company recorded a half-year loss of US$12 million on revenue of US$156 million, while its reported revenue for 2026 reached US$273 million.

Its experimental treatment ITM-11 encountered a regulatory setback after the US FDA rejected an application because of concerns related to the manufacturing process at a third-party facility.

ITM-11 is designed to use lutetium-177 to treat gastroenteropancreatic neuroendocrine tumours, a group of uncommon cancers affecting areas including the stomach, pancreas and digestive system.

ITM intends to submit the treatment for regulatory review again. Under the proposed transaction, Telix could make additional payments of up to US$700 million if the therapy receives US approval and reaches specified commercial milestones.

Deal Could Reshape Telix's Global Operations

The acquisition is expected to provide Telix with increased exposure to isotope production while broadening its position across the radiopharmaceutical supply chain.

Analysts have pointed to the growing demand for lutetium-177 as an important factor behind the transaction. Research and development programs involving the isotope are expanding internationally, with numerous potential therapies being developed.

The transaction is expected to be completed by the end of 2026, subject to approval from Telix shareholders and the satisfaction of other required conditions.

If completed, the deal would represent a major expansion for an Australian healthcare technology company and further connect Telix with the rapidly developing global radiopharmaceutical market. It also reflects the increasing importance of specialised isotopes in modern cancer diagnosis and targeted treatment.

Source: AAP, Derek Rose.